ArticlePlastic and reconstructive surgery. Global open2025
Efficacy of Batroxobin on Ischemia-Reperfusion Injury in Epigastric Artery Island Flaps in Rats.
Article in Plastic and reconstructive surgery. Global open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Batroxobin is a thrombin-like enzyme derived from snake venom that exhibits not only antithrombotic effects due to its fibrinogen-degrading effects, but also inflammatory and tissue-protective effects by inhibiting neutrophil extracellular traps (NETs). This study aimed to investigate the effects of batroxobin on NET suppression and flap necrosis reduction in a rat island flap ischemia-reperfusion injury (IRI) model. Methods: An island flap was created on the abdominal wall of a rat. The vascular pedicle was clamped for 6 hours and then released to establish the IRI model. Batroxobin (10 BU/kg) was administered intraperitoneally at the time of clamp release in the experimental group, whereas the control group received normal saline. The extent of blood perfusion within the flap was assessed using laser Doppler imaging, and NET expression was evaluated via S100A9 staining. Results: Laser Doppler imaging exhibited the accelerated reperfusion area in batroxobin-treated rats compared with controls; 7 days postreperfusion, the rate of recovered area was 78.1% in the batroxobin group versus 44.6% in the control group. Histological analysis at 48 hours postreperfusion by S100A9 staining showed significantly reduced NETs in the batroxobin group; the S100A9-positive cells were 199.4 ± 63.7 per low power field in the batroxobin group versus 352.0 ± 76.4 per low power field in the control group. These findings indicate that batroxobin effectively preserved blood perfusion with a protective effect against tissue injury in the flap IRI model. Conclusions: These findings suggest that batroxobin may serve as a promising therapeutic agent for mitigating inflammatory tissue damage caused by IRI.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.